Other News To Note
• Curis Inc., of Lexington, Mass., inked an agreement with yhe Leukemia & Lymphoma Society (LLS) to support ongoing development of its oral small-molecule dual Pi3 kinase and HDAC inhibitor CUDC-907 for B-cell lymphoma and multiple myeloma. LLS will fund approximately half of the direct costs of the development of CUDC-907, up to $4 million.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST